ReviewThe Journal of clinical investigation2000
Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer.
Review in The Journal of clinical investigation, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.Molecular therapy : the journal of the American Society of Gene Therapy · 2010Trial
- Establishing an RNA Sensor with High Sensitivity and Dynamic Range Utilizing a Signal Amplifier Platform.ACS synthetic biology · 2026Article
- Establishing an RNA sensor with high sensitivity and dynamic range utilizing a signal amplifier platform.bioRxiv : the preprint server for biology · 2025Article
- Immunotherapy by mesenchymal stromal cell delivery of oncolytic viruses for treating metastatic tumors.Molecular therapy oncolytics · 2022Review
- Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements.Frontiers in immunology · 2022Review
- Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?Human vaccines & immunotherapeutics · 2021Review
- Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs.Scientific reports · 2021Article
- Progress in the Application of Immune Checkpoint Inhibitor-Based Immunotherapy for Targeting Different Types of Colorectal Cancer.Frontiers in oncology · 2021Review
- Oncolytic Viruses and Hematological Malignancies: A New Class of Immunotherapy Drugs.Current oncology (Toronto, Ont.) · 2020Review
- CRISPR-Cas12a with an oAd Induces Precise and Cancer-Specific Genomic Reprogramming of EGFR and Efficient Tumor Regression.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Optimizing oncolytic virotherapy in cancer treatment.Nature reviews. Drug discovery · 2019Review
- Combing oncolytic adenovirus expressing Beclin-1 with chemotherapy agent doxorubicin synergistically enhances cytotoxicity in human CML cells in vitro.Acta pharmacologica Sinica · 2018Article
- Oncolytic virus and PD-1/PD-L1 blockade combination therapy.Oncolytic virotherapy · 2018Review
- Genetically Engineered Vaccinia Viruses As Agents for Cancer Treatment, Imaging, and Transgene Delivery.Frontiers in oncology · 2017Review
- Novel oncolytic viral therapies in patients with thoracic malignancies.Oncolytic virotherapy · 2017Review
- Molecular imaging of oncolytic viral therapy.Molecular therapy oncolytics · 2015Review
- Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy.Oncolytic virotherapy · 2015Review
- Arming viruses in multi-mechanistic oncolytic viral therapy: current research and future developments, with emphasis on poxviruses.Oncolytic virotherapy · 2014Review
- Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.Frontiers in immunology · 2014Review
- Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia.Oncotarget · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.